🔥 What’s Hot on CardioAdvocate
Timely updates. Clinical relevance. Clear next steps.
Medicine evolves. We highlight what actually changes how people should think, ask questions, or advocate for themselves.
We don’t chase attention. We track meaning.
🧬 Obesity Rewires the Sarcomere: Troponin I Modification Drives Contractile Dysfunction in HFpEF
LANDMARK SCIENCE | Johns Hopkins / Science | April 23, 2026
What changed
A landmark study from Johns Hopkins, published in Science on April 23, 2026, reveals for the first time that severe obesity (BMI >40 kg/m²) causes a specific chemical modification of troponin I — phosphorylation at Thr181 — in the hearts of patients with HFpEF, directly weakening cardiomyocyte contraction. This is not a hemodynamic bystander effect; it is a molecular lesion at the sarcomere level. Cardiomyocytes from HFpEF-plus-obesity hearts generated significantly less active force than those from lean HFpEF or non-failing hearts, and the troponin I Thr181 modification was present only in the obese-HFpEF group. Crucially, in patients treated with GLP-1 receptor agonists who lost >10% body weight, cardiomyocyte contraction returned to near-normal — demonstrating reversibility.
Why this matters
This redefines how we think about the “obese phenotype” of HFpEF. It is not just hemodynamic overload, pericardial restraint, or inflammation alone — it is a sarcomere-level disease. Three immediate implications: (1) GLP-1 RA-mediated weight loss may be disease-modifying at the myofilament level, not just symptom-relieving; (2) the authors explicitly caution against using cardiac myosin inhibitors (mavacamten, aficamten) in severely obese HFpEF patients — these drugs would further suppress already-weakened sarcomere function; (3) troponin I Thr181 phosphorylation is a potential precision-medicine target. This is the kind of translational science that changes clinical phenotyping — and it adds a new mechanistic chapter to “The Enigma” HFpEF story.
Who should care
Patients with HFpEF and severe obesity (BMI >40) — ask whether GLP-1 RA-driven weight loss should be part of your treatment plan
Anyone being considered for a cardiac myosin inhibitor (mavacamten, aficamten) clinical trial — ensure your cardiologist knows about the obesity caution
Clinicians phenotyping HFpEF — this strengthens the case for treating obesity as a cardiac disease, not a comorbidity
Go deeper →
“The Enigma” — HFpEF (CardioAdvocate Phenotype)
Science — Full Text (Hopkins, April 23, 2026)
🚨 Myth Busted: SGLT2 Inhibitors Are NOT Antiarrhythmic Drugs — DARE-AF Sharpens the Story
PRACTICE-CHANGING | Circulation | 2026
What changed
The DARE-AF randomized clinical trial, published in Circulation in 2026, is a pivotal negative result. In 200 patients with persistent atrial fibrillation undergoing first-time catheter ablation who did not have diabetes, heart failure, or CKD, three months of dapagliflozin 10 mg daily did not reduce AF burden (7.5% vs. 8.1%, P = 0.48) or recurrence (29.5% vs. 28.0%; HR 1.11, 95% CI 0.66–1.86) compared with usual care. Contrast this with observational data and meta-analyses showing SGLT2 inhibitors reduce AF recurrence by ~41% post-ablation — but those studies were in patients with diabetes, HF, or CKD.
Why this matters
Social media and conference hallway chatter have increasingly promoted SGLT2 inhibitors as a novel antiarrhythmic class. Meta-analyses across 52 RCTs show a ~14% reduction in incident AF; observational post-ablation data look even better. DARE-AF tells us why we can’t extrapolate: the AF-reduction signal in DAPA-HF, EMPEROR-Reduced, and CREDENCE almost certainly reflects reverse remodeling of the atrial substrate — volume unloading, lower atrial pressures, anti-fibrotic effects on diseased myocardium — not a direct ion-channel mechanism. The clean translation: SGLT2 inhibitors are cardiometabolic drugs with downstream antiarrhythmic consequences — not antiarrhythmic drugs with cardiometabolic side benefits. Use them aggressively in HF, CKD, and diabetes (where AF prevention is a bonus). Don’t start them as standalone AF prophylaxis in metabolically healthy patients. A 2026 Circulation editorial puts it perfectly: “Overstretching the evidence.”
Who should care
Patients with AFib who have been told an SGLT2 inhibitor will “treat” their rhythm — ask whether you also have HF, CKD, or diabetes (the populations where the benefit was actually shown)
Patients post-ablation deciding whether to add dapagliflozin for AF prophylaxis alone
Clinicians and educators tempted to call SGLT2i “a new antiarrhythmic class”
Go deeper →
“Drinking Buddies” — Atrial Fibrillation (CardioAdvocate Phenotype)
DARE-AF — Full Text (Circulation)
Circulation Editorial — “Overstretching the Evidence”
EHJ Cardiovascular Pharmacotherapy — Meta-Analysis (52 RCTs)
💊 GLP-1 Receptor Agonists Cut CV and Kidney Risk by 15–19% in Type 1 Diabetes — Filling a Massive Evidence Gap
EVIDENCE EXPANSION | Nature Medicine | April 2026
What changed
A large-scale observational study from the Johns Hopkins Bloomberg School of Public Health, published in Nature Medicine in April 2026, provides the first robust evidence that GLP-1 receptor agonists (semaglutide, tirzepatide) improve cardiovascular and renal outcomes in patients with type 1 diabetes — a population systematically excluded from every major GLP-1 RA cardiovascular outcomes trial to date (LEADER, SUSTAIN-6, SELECT, SURPASS-CVOT). Analyzing ~175,000 U.S. T1D patients via sequential target trial emulation: 15% lower 5-year MACE, 21% lower MI, 19% lower end-stage kidney disease, 16% lower all-cause mortality, and 22% greater likelihood of ≥10% weight loss.
Why this matters
The GLP-1 RA cardiovascular revolution has been built entirely on type 2 diabetes and obesity data. T1D patients — who face 2–4× the cardiovascular mortality of the general population — have been left out. Two safety concerns have historically blocked off-label use: hypoglycemia and diabetic ketoacidosis. This study addresses both: hospitalization for hypoglycemia decreased 18%, and DKA decreased 17%. A randomized CVOT in T1D is still urgently needed, but for cardiologists co-managing T1D patients with endocrinology, this study supports the conversation about GLP-1 RA initiation in overweight or obese T1D patients with elevated CV risk.
Who should care
Patients with type 1 diabetes who have been told GLP-1 RAs “aren’t for you” — ask your endocrinologist and cardiologist about this data
T1D patients with overweight/obesity, established CV disease, or albuminuria/CKD
Clinicians co-managing T1D patients across endocrinology and cardiology
Go deeper →
“The Sweet Spot” — Diabetes & Cardiovascular Risk (CardioAdvocate Phenotype)
🏃 GLP-1 + Healthy Lifestyle: Complementary, Not Competing — 43% MACE Reduction When Combined
PATIENT-CENTERED | Harvard T.H. Chan School | April 2026
What changed
A Harvard T.H. Chan School of Public Health study demonstrates that GLP-1 receptor agonist use and healthy lifestyle habits are additive — not substitutes — for cardiovascular risk reduction in type 2 diabetes. Individuals who used a GLP-1 RA and adhered to 6–8 healthy habits (regular exercise, no smoking, limited alcohol, healthy diet, healthy weight, restorative sleep, social connection, stress management) had a 43% lower risk of major adverse cardiovascular events compared with those using neither strategy.
Why this matters
One of the most common patient questions — and clinical debates — is whether pharmacotherapy “replaces” lifestyle intervention. This study quantifies what many of us suspected: the benefits stack. A patient on semaglutide who also exercises, doesn’t smoke, limits alcohol, and maintains a healthy diet does substantially better than a patient relying on either strategy alone. The clinical talking point: “This medication works with your lifestyle changes, not instead of them.”
Who should care
Anyone considering or already taking a GLP-1 RA who wonders whether lifestyle still matters (it does — profoundly)
Patients with type 2 diabetes and elevated cardiovascular risk
Clinicians needing a clear, quantitative answer to the “medication vs. lifestyle” question
Go deeper →
🚨 Myth Busted: LAAO Is NOT a Universal Replacement for Blood Thinners — CHAMPION-AF in Context
MYTH BUSTING | CHAMPION-AF + CLOSURE-AF | April 2026
What changed
Social media and some patient advocacy channels have amplified CHAMPION-AF’s headline result to suggest that the Watchman device is now a superior alternative to anticoagulation for all AF patients. What CHAMPION-AF actually showed: noninferiority of LAAO vs. NOACs (5.7% vs. 4.8%), with superior reduction in non-procedural bleeding (10.9% vs. 19.0%). However, ischemic stroke was numerically higher in the device arm (3.2% vs. 2.2%), and device thrombus occurred in 4.8% of imaged patients.
Why this matters
The bleeding benefit is real and clinically important for the right patient. But combined with CLOSURE-AF’s neutral result, the evidence base says: reserve LAAO for patients with high bleeding risk who truly cannot tolerate long-term anticoagulation. Patient selection is everything. If your patient is doing well on a DOAC, there is no compelling reason to switch to a device.
Who should care
AF patients who have been offered or are considering LAA closure
Anyone told LAAO is “better than” blood thinners based on CHAMPION-AF headlines
Clinicians referring patients for LAAO — criteria should be carefully evaluated
Go deeper →
Drinking Buddies — AFib (Phenotype)
⚡ ADVENT-LTO: Pulsed Field Ablation Holds Strong at 4 Years — Fewer Repeat Procedures
NEW | Nature Medicine | April 2026
What changed
The ADVENT-LTO study provides the longest randomized follow-up of pulsed field ablation (PFA) versus conventional thermal ablation in paroxysmal atrial fibrillation. At 4 years in 364 patients: treatment success was 72.8% PFA vs. 64.3% thermal (numerically favoring PFA). Freedom from hospital-based arrhythmia intervention was 85.6% PFA vs. 78.6% thermal (HR 0.64), with fewer repeat ablations (10.4% vs. 17.7%). No new long-term safety signals emerged — the tissue-selectivity advantage of PFA is preserved at 4 years.
Why this matters
The 7-percentage-point gap in repeat ablation rates is clinically meaningful and suggests PFA lesions may be more complete or durable than thermal lesions over time. For patients and referring physicians asking about PFA, the message is clear: it works at least as well as conventional ablation, with a better safety profile and possibly fewer redo procedures.
Who should care
Patients with AF considering ablation or facing a repeat procedure
Anyone who has had thermal ablation and is experiencing recurrence
Clinicians counseling patients on ablation technology options
Go deeper →
Drinking Buddies — AFib (Phenotype)
💊 Tirzepatide in HFpEF: EMA Adds SUMMIT Data to Label — Evidence Supports Cardiac Benefit Beyond Weight Loss
NEW | EMA Label Update • SUMMIT Trial | April 2026
What changed
The European Medicines Agency has updated tirzepatide’s product information to include SUMMIT trial results in HFpEF with obesity. The SUMMIT data showed a 38% reduction in CV death or worsening HF events (HR 0.62) and a clinically meaningful +6.9 point KCCQ-CSS improvement in quality of life. Potent weight reduction plus favorable changes in lipids, blood pressure, inflammation, and endothelial function target the central pathophysiologic drivers of obesity-related HFpEF.
Why this matters
The label update is a green light to prescribe tirzepatide in obese HFpEF patients with confidence that the evidence supports cardiac benefit beyond weight loss. The SUMMIT NNT of approximately 19 over 52 weeks competes favorably with many HF therapies already in use. The EMA stopped short of a standalone HFpEF indication (that would require a dedicated Phase 3 outcomes trial), but the clinical takeaway is clear.
Who should care
Patients with HFpEF and obesity — particularly those with shortness of breath, fatigue, and fluid retention
Anyone on tirzepatide for weight loss or diabetes who also has heart failure symptoms
Clinicians managing the overlap of obesity and HFpEF
Go deeper →
The Enigma — HFpEF (Phenotype)
See No Evil — Obesity (Phenotype)
⚠️ Metabolic Surgery vs. GLP-1 RAs: 10-Year Data Favor Surgery — But Context Matters
ALERT | Nature Medicine | April 2026
What changed
A major observational study compared 1,657 metabolic surgery patients with 2,275 matched GLP-1 RA–treated patients with T2DM and obesity over 10 years. Surgery showed lower all-cause mortality (9.0% vs. 12.4%), 35% lower MACE, 47% reduction in nephropathy, and 54% reduction in retinopathy. Weight loss was 21.6% vs. 6.8%; HbA1c improvement was −0.86% vs. −0.23%.
Why this matters
These are observational data with inherent confounders — surgical patients are self-selected, and GLP-1 RA doses and agents varied over the decade. But the magnitude of difference in microvascular outcomes is striking and aligns with prior bariatric surgery datasets. The key takeaway is not that GLP-1 RAs are inadequate — they remain transformative — but that metabolic surgery should remain front and center in shared decision-making for patients with BMI ≥35 and T2DM who are surgical candidates.
Who should care
Patients with BMI ≥35 and type 2 diabetes weighing their treatment options
Anyone on a GLP-1 RA who has been told surgery “isn’t necessary anymore”
Clinicians navigating the surgery-vs-medication conversation with patients
Go deeper →
See No Evil — Obesity (Phenotype)
The Sweet Spot — Diabetes (Phenotype)
📜 2026 ACC/AHA/NLA Dyslipidemia Guidelines: The Most Significant U.S. Lipid Update in Over a Decade
LANDMARK | JACC & Circulation | March 2026
What changed
The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol, led by Roger Blumenthal and colleagues, represents a seismic shift in American lipid management. After 13 years of “percent reduction only,” absolute LDL-C and non-HDL-C treatment goals have returned — with tiered targets matching the intensity of a patient’s risk. The new PREVENT-ASCVD equations replace the Pooled Cohort Equations, with recalibrated thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%). Universal Lp(a) screening is now Class I for all adults. The Calculate-Personalize-Reclassify (CPR) framework replaces the old clinician-patient risk discussion with a structured, evidence-based algorithm. ApoB receives COR 2a. Coronary artery calcium gets a full 6-recommendation tiered system. Dietary supplements and CoQ10 both receive COR 3: No Benefit. New drug classes enter the algorithm: bempedoic acid, inclisiran, evinacumab, and olezarsen. And special populations — HIV, CKD, pregnancy, older adults — get dedicated, nuanced recommendations for the first time in a U.S. cholesterol guideline.
Why this matters
This guideline fundamentally changes the standard of care in the United States. Every CardioAdvocate article affected has been updated to reflect the new recommendations — 20 articles across the site. The return of absolute LDL-C goals means patients finally have a number to aim for, not a percentage to calculate. Universal Lp(a) screening means every adult should know their number. The CPR framework means risk assessment is no longer a one-time conversation but a layered, personalized process. And the courage to assign COR 3: No Benefit to supplements and CoQ10 — despite industry pressure — sends a clear message: evidence matters more than marketing. For our patients, this guideline also makes it significantly easier to get insurance authorization for therapies that were previously classified only as “may be considered” — now backed by hard guideline recommendations.
CardioAdvocate perspective
We applaud the direction and thank the writing committee for a comprehensive, forward-thinking document. But we remind our readers: much of what feels “new” in these guidelines is what preventive cardiologists and lipidologists have been practicing for years. We don’t wait for guidelines to catch up to the evidence — we use them for their intended purpose: to guide us, alongside position papers, expert consensus, and RCTs that haven’t yet made it into formal recommendations. We also continue to differ in certain areas — read our editorial for specifics.
Who should care
Every patient with elevated cholesterol, established ASCVD, or cardiovascular risk factors
Anyone taking (or considering) a statin, ezetimibe, PCSK9 inhibitor, or bempedoic acid
Patients who have never had their Lp(a) tested
Clinicians managing lipids in primary or secondary prevention
Go deeper →
Follow the Leader — Lipid Guidelines (Phenotype — Updated March 2026)
Little Napoleon Complex — Lipoprotein(a) (Phenotype — Updated)
A Picture Worth a Thousand Words — CAC (Phenotype — Updated)
There’s an App for That — Risk Calculators (Phenotype — Updated)
Hiding in Plain Sight — FH (Phenotype — Updated)
📝 CardioAdvocate Editorial: “A Step in the Right Direction”
NEW INSIGHT | CardioAdvocate Editorial | March 2026
What changed
CardioAdvocate has published a comprehensive editorial response to the 2026 ACC/AHA/NLA Dyslipidemia Guidelines. We break down what we applaud — including the return of absolute LDL-C goals, universal Lp(a) screening, the CPR personalization framework, and the courage to assign COR 3: No Benefit to supplements. We also detail where we continue to differ: CAC >300 should confer secondary prevention-equivalent risk (not waiting for >1000), ApoB deserves higher prominence given the growing problem of LDL-C discordance especially at lower levels, and inclisiran’s real-world LDL-C lowering may not match trial data. Most importantly, we discuss VESALIUS-CV — the evolocumab primary prevention trial showing 25% MACE reduction in high-risk patients without prior MI or stroke — and why clinicians don’t have to wait for the next guideline iteration to apply this evidence now.
Why this matters
Guidelines are guides, not guardrails. They represent the minimum standard of care, not the ceiling. This editorial reinforces CardioAdvocate’s core philosophy: personalize based on the best available evidence as it applies to the individual patient in front of you. Use guidelines, position papers, expert consensus, and landmark RCTs — don’t limit yourself to any single document. The CPR framework itself tells us to Calculate, Personalize, and Reclassify. We agree. And we’re grateful to the writing committee for the most important U.S. lipid document in over a decade.
Who should care
Patients who want to understand what the new guidelines mean for their care
Clinicians deciding how aggressively to treat based on CAC, ApoB, and Lp(a)
Anyone interested in how VESALIUS-CV changes the primary prevention conversation right now
Go deeper →
A Step in the Right Direction — 2026 Guidelines Editorial (Insight — NEW)
Follow the Leader — Lipid Guidelines (Phenotype — Updated)
🔬 VESALIUS-CV: PCSK9 Inhibitors Aren’t Just for Heart Attack Survivors Anymore
NEW | NEJM Landmark | 2026
What changed
The VESALIUS-CV trial (N=12,257) tested evolocumab vs. placebo in high-risk patients without prior MI or stroke — a true primary prevention PCSK9 inhibitor trial. Results: 25% reduction in 3-point MACE (HR 0.75; 95% CI 0.65–0.86; P<0.001), 36% reduction in MI, 19% reduction in 4-point MACE (including revascularization), and numerically fewer deaths in the evolocumab arm with extended follow-up. This is the first large-scale trial to demonstrate PCSK9 inhibitor benefit in a population that has never had a heart attack or stroke.
Why this matters
Patients with diabetes, advanced atherosclerosis, or high Lp(a) who haven’t yet had a cardiovascular event now have RCT-level evidence supporting aggressive LDL lowering with PCSK9 inhibition. This dovetails with the 2026 ACC/AHA dyslipidemia guideline’s return to treat-to-target and its emphasis on lifetime risk. The era of waiting for a heart attack before using PCSK9 inhibitors may be over.
Who should care
High-risk patients without prior heart attack or stroke who are not at LDL goal
Patients with diabetes, advanced subclinical atherosclerosis, or elevated Lp(a)
Clinicians still reserving PCSK9 inhibitors only for secondary prevention
Go deeper →
A Step in the Right Direction — Guidelines Editorial (Insight)
Follow the Leader — Lipid Guidelines (Phenotype)
🫀 The Cardio-Hepatic Connection: MASLD/MASH Enters the Cardiometabolic Mainstream
NEW | Circulation & NEJM | March 2026
What changed
A Circulation scientific statement has formalized screening and management recommendations for metabolic dysfunction-associated steatotic liver disease (MASLD) in cardiovascular patients — the first time a major U.S. cardiovascular society has formally recognized MASLD as a CV risk factor. Separately, semaglutide’s Phase 3 MASH data (NEJM) shows 62.9% MASH resolution at interim analysis vs. 34.3% with placebo. And Eli Lilly’s SYNERGY-NASH trial is evaluating MASH resolution with tirzepatide — potentially positioning it as a triple-threat for obesity, MASH, and CV risk.
Why this matters
MASLD affects an estimated 30% of the global population and is independently associated with increased cardiovascular morbidity and mortality. GLP-1 RAs and SGLT2 inhibitors — medications already in the cardiologist’s toolkit — show dual liver and cardiovascular benefits. A simple FIB-4 score or hepatic steatosis index can flag patients who need further evaluation. The drugs we are already prescribing for diabetes and obesity may be treating liver disease simultaneously.
Who should care
Patients with obesity, type 2 diabetes, or metabolic syndrome who have never had their liver evaluated
Anyone on a GLP-1 RA or SGLT2 inhibitor — these may be protecting the liver too
Clinicians who treat cardiometabolic disease but don’t routinely screen for MASLD
Go deeper →
MASLD Cardiovascular Screening Statement (Circulation)
Semaglutide Phase 3 for MASH (NEJM)
The Sweet Spot — Diabetes (Phenotype)
See No Evil — Obesity (Phenotype)
📖 ESC Scientific Statement: Metabolic Risk Factors and the Heart
NEW | European Heart Journal | March 2026
What changed
The European Society of Cardiology just published a major scientific statement from five ESC working groups synthesizing the molecular and cellular mechanisms linking obesity, type 2 diabetes, and dyslipidemia to atherosclerosis, heart failure, ischemic heart disease, and arrhythmias. The statement introduces the cardiovascular-kidney-metabolic (CKM) syndrome staging framework (Stages 0–4), proposes a paradigm shift from treating CVD as a vascular problem to understanding it as a downstream consequence of systemic metabolic dysfunction, and draws a sharp mechanistic distinction between HFpEF (metabolic excess and nutrient toxicity) and HFrEF (metabolic insufficiency and energetic failure).
Why this matters
This statement validates the integrated cardiometabolic framework that CardioAdvocate has been building across our Phenotype articles. It reinforces that obesity, diabetes, dyslipidemia, and heart disease are not separate problems — they are interconnected metabolic drivers feeding the same vicious cycles. It also highlights how SGLT2 inhibitors and GLP-1 receptor agonists work through pleiotropic metabolic mechanisms far beyond glucose lowering — and why combining them may be synergistic. For patients, the takeaway is clear: metabolic health is cardiovascular health, and addressing the root metabolic dysfunction — not just individual risk factors in isolation — is the path forward.
Who should care
Patients managing multiple cardiometabolic conditions (obesity + diabetes + heart disease + CKD)
Anyone wondering why their cardiologist now talks about weight and metabolism
Clinicians seeking a unified mechanistic framework for the metabolic-cardiovascular connection
Go deeper →
See No Evil — Obesity (Phenotype — NEW)
The Enigma — HFpEF (Phenotype)
Drinking Buddies — AFib (Phenotype)
The Sweet Spot — Diabetes (Phenotype)
💊 Oral PCSK9 Inhibitor Enlicitide — A Pill That Rivals Injections
NEW | Landmark Trial | February 2026
What changed
The CORALreef Lipids trial (NEJM, February 2026) demonstrated that enlicitide — a once-daily oral PCSK9 inhibitor — achieved 57% LDL-C reduction at 24 weeks in 2,909 patients, matching injectable PCSK9 inhibitors in a simple pill form. Over 70% of patients reached LDL-C <70 mg/dL with ≥50% reduction. Additionally, Lp(a) was reduced by 28%. Adverse events were comparable to placebo with 97% adherence.
Why this matters
Injectable PCSK9 inhibitors are dramatically underused despite proven efficacy — fewer than half of patients with established ASCVD currently reach LDL cholesterol goals. As lead investigator Ann Marie Navar (UT Southwestern) stated: an oral therapy this effective has the potential to dramatically improve cardiovascular prevention on a population level. The CORALreef Outcomes trial (completion 2029) will test whether this translates to reduced cardiovascular events.
Who should care
Patients not at LDL goal despite maximally tolerated statin therapy
Those who have declined or discontinued injectable PCSK9 inhibitors
Anyone with ASCVD or FH requiring aggressive lipid lowering
Clinicians seeking alternatives to injection burden
Go deeper →
Hiding in Plain Sight: Familial Hypercholesterolemia (Phenotype)
Follow the Leader — Lipid Guidelines (Phenotype)
🧬 2026 Is the Year of Lp(a) — From Research Curiosity to Treatment Target
Pipeline Watch | February 2026
What changed
Five drugs targeting lipoprotein(a) are advancing toward phase 3 readouts. Pelacarsen results are expected H1 2026, with regulatory filings to follow. OCEAN(a)-Outcomes for olpasiran completion December 2026. Muvalaplin, an oral small molecule achieving ~65% Lp(a) reduction, has a CVOT in progress. These trials will answer the critical question: does lowering Lp(a) reduce cardiovascular events?
Why this matters
If the answer is yes, Lp(a) testing may become essential for every patient with premature cardiovascular disease or a family history of heart attack or stroke. We may be witnessing the emergence of an entirely new treatment paradigm based on genetic risk rather than lifestyle modification alone.
Key trials to watch
Pelacarsen (Lp(a)HORIZON) — Novartis/Ionis ASO targeting Lp(a) mRNA
Olpasiran (OCEAN(a)-Outcomes) — Amgen siRNA targeting Lp(a)
Lepodisiran — Eli Lilly siRNA
Muvalaplin — Oral small molecule (~65% reduction)
Go deeper →
Little Napoleon Complex — Lipoprotein(a) (Phenotype)
🏋️ Myth Busted: Strength Training Is Cardioprotective — Your Muscles Are an Endocrine Organ
MYTH BUSTING | HHS Guidelines • Stanford Lifestyle Medicine • Endocrine Reviews | March 2026
What changed
A persistent myth — circulating among patients and even some clinicians — holds that only aerobic exercise (“cardio”) protects the heart, and that strength training is purely cosmetic. The evidence dismantles this completely. The U.S. HHS Physical Activity Guidelines explicitly recommend at least 2 days per week of resistance training as a foundation of metabolic health. Stanford’s Lifestyle Medicine program now formally frames skeletal muscle as an independent cardiometabolic protective factor: higher lean mass is associated with improved insulin sensitivity, lower inflammatory markers, better blood pressure regulation, and reduced all-cause mortality. Most powerfully, exercise physiologists now recognize skeletal muscle not as passive tissue, but as a true endocrine organ — one that contracts to secrete hundreds of signaling molecules called myokines. These myokines (including IL-6, irisin, BDNF, and others) communicate with the brain, heart, liver, adipose tissue, bone, pancreas, gut, and immune system. IL-6 alone — released during each bout of exercise — drives anti-inflammatory effects, fat browning, glucose uptake, and even GLP-1 secretion from the gut. Resistance training uniquely activates myokine cascades that aerobic exercise alone cannot replicate.
Why this matters
This is not incremental science — it is a paradigm shift. Prescribing only aerobic exercise is leaving significant cardiometabolic benefit on the table. For patients with obesity and insulin resistance, muscle is the primary site of glucose disposal — building it improves metabolic syndrome independent of weight loss. For patients with HFpEF and sarcopenia (muscle wasting), resistance training may be as important as any pill we prescribe. For patients with type 2 diabetes, myokines released during resistance exercise improve insulin signaling through entirely separate mechanisms from GLP-1 drugs. Aerobic and resistance exercise are complementary, not competing. Prescribe both — and think of resistance training as a form of polypharmacy your body produces for free.
Who should care
Anyone told to “just walk more” for heart health — walking is excellent, and it’s not the whole answer
Patients with obesity, type 2 diabetes, or metabolic syndrome whose program doesn’t include resistance training
Older adults with muscle loss (“sarcopenia”) and heart failure — two problems that compound each other
Clinicians who only write aerobic activity prescriptions
Go deeper →
Killer Workouts — The Adult Athlete (Phenotype)
The Enigma — HFpEF (Phenotype)
Stanford Lifestyle Medicine — Healthy Habits in Your 40s & 50s